A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo
NCT05752032 is an observational study sponsored by ICM Co. Ltd.. As of 21 Nov 2026, it is active and no longer recruiting. It studies Placebo in Osteoarthritis, Knee. The registry lists an enrollment of 10 participants at 2 sites in 1 country. The registry lists a start date of 16 Mar 2023 and a primary completion date of 31 Jul 2029.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05752032 |
| Status | Active not recruiting |
| Study type | Observational study |
| Lead sponsor | ICM Co. Ltd. |
| Enrollment | 10 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Osteoarthritis, Knee |
| Drugs | Placebo |
| Start | 16 Mar 2023 |
| Primary completion | 31 Jul 2029 |
| Study completion | 31 Jul 2029 |
| Last update posted | 3 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alison Heald, MD
ICM Co. Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital
Adelaide, South Australia
- Barwon Health
Geelong, Victoria
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05752032
Each answer restates registry values shown on this page.
What is NCT05752032?
NCT05752032 is an observational study sponsored by ICM Co. Ltd.. It studies Placebo in Osteoarthritis, Knee.
Is NCT05752032 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT05752032?
The registry names Alison Heald, MD (study director, ICM Co. Ltd.) as the overall official.
Where does NCT05752032 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: Australia.
Which drugs does NCT05752032 study?
The registered drug and biological interventions are Placebo.
When is NCT05752032 expected to complete?
The registry lists a primary completion date of 31 Jul 2029 and a study completion date of 31 Jul 2029. The sponsor last updated the record on 3 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.